On July 31, 2026, Hong Kong stocks saw a structural rally amid repeated fluctuations. In the afternoon, the AI healthcare concept suddenly surged, becoming the most eye-catching sector in the market. By the close, the Hang Seng Index edged up 0.35% to 25,210 points, while the Hang Seng Healthcare Index, which tracks the sector, jumped 3.2%, with many AI healthcare stocks posting impressive gains.
AI healthcare concept surged collectively; many stocks rose by double digits
This afternoon, the AI healthcare sector was almost entirely in the green. Yidu Tech (2158.HK) at one point soared over 18% intraday and closed up 14.5% at HK$6.32; Ping An Good Doctor (1833.HK) rose 11.2%; Alibaba Health (0241.HK) gained 7.8%; JD Health (6618.HK) advanced 5.6%. In addition, a number of small- and mid-cap AI healthcare stocks such as Zhongkang Holdings and Medlive jumped over 10%, creating a clear sector effect.
In terms of capital flows, southbound capital saw a net inflow of about HK$7.2 billion into Hong Kong stocks today, of which the pharmaceutical and healthcare sector received net buying of about HK$1.5 billion, accounting for more than 20%. HKEX data showed that turnover in healthcare-related ETFs nearly doubled from the previous day, indicating that institutional funds are rapidly adding positions.
Policy tailwinds and capital attention change the industry logic
On the news front, the National Health Commission officially issued the “Guiding Opinions on Accelerating the Development of ‘AI + Medical Health’” yesterday (July 30), proposing to achieve major breakthroughs in core areas such as medical imaging analysis, auxiliary diagnosis, and drug R&D by 2028, and cultivate a batch of internationally competitive AI healthcare leaders. This top-level design directly ignited market enthusiasm.
Meanwhile, Guangdong Province and Shanghai have also announced the inclusion of AI healthcare in a new batch of “application scenario opening lists”, sending a clear signal of industrial support. The industry generally believes that policies will drive both demand and supply, opening broad space for AI healthcare monetization.
Multiple institutions interpret the AI healthcare sector surge
- UBS: AI healthcare is on the eve of commercial implementation, and HK-listed targets are globally scarce. It recommends focusing on leaders in auxiliary diagnosis and drug R&D.
- Guosen Securities: Driven by policy, internet medical platforms are expected to use AI to reduce costs and increase efficiency; it is optimistic about the monetization potential of health management scenarios.
- Zhongtai International: Short-term trading sentiment is strong, but divergence is inevitable; investors need to select stocks with clinical data and product implementation.
Southbound capital accelerates entry, highlighting HK stock allocation value
It is worth noting that southbound capital has recorded inflows for the 8th consecutive trading day, exceeding HK$40 billion in total, reflecting mainland investors' recognition of the long-term allocation value of Hong Kong stocks. With the A/H premium ratio still as high as 135%, relatively undervalued Hong Kong assets are clearly attractive. As a new economy direction, AI healthcare has absorbed a significant portion of incremental capital.
The strength in AI healthcare also drove the broader biotech sector. The HK 18A biotech index rose 4.1%, and many pre-profit biotech stocks performed well. Market participants believe AI technology could significantly lower drug R&D costs, benefiting the innovative drug industry chain.
Risk warnings and market outlook
Despite high market sentiment, the risk of divergence after a sharp short-term surge cannot be ignored. Some companies are still loss-making, and the commercialization path of AI healthcare has yet to be verified. Investors should distinguish company fundamentals and focus on targets with genuine technical moats, clinical data, and sustainable orders.
Overall, AI healthcare may be another growth track with industrial logic support for Hong Kong stocks after new energy and semiconductors. With the resonance of policy, capital, and technology, the long-term space of this track is worth looking forward to. However, short-term share price fluctuations are inevitable; investors are advised to build positions on dips rather than blindly chase highs.
